Congestive Heart Failure Treatment Devices Market
Report ID: SQMIG35A3424
Report ID: SQMIG35A3424
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35A3424 |
Region:
Global |
Published Date: May, 2026
Pages:
157
|Tables:
152
|Figures:
78
Global Congestive Heart Failure Treatment Devices Market size was valued at USD 6.2 Billion in 2024 and is poised to grow from USD 6.55 Billion in 2025 to USD 10.2 Billion by 2033, growing at a CAGR of 5.69% during the forecast period (2026-2033).
The primary driver shaping the congestive heart failure treatment devices market is the rising prevalence of heart failure linked to aging populations and chronic disease burdens, which has steadily expanded demand for device-based therapies. This market encompasses implantable devices such as cardiac resynchronization therapy systems, implantable cardioverter-defibrillators, left ventricular assist devices and implantable hemodynamic monitors, plus ambulatory remote-monitoring platforms. It matters because device interventions can reduce hospitalizations and mortality, easing economic pressure on health systems. Over time the sector evolved from open surgical pumps to durable, minimally invasive implants and sensor-enabled remote care, exemplified by HeartMate LVADs and CardioMEMS sensors.
Building on device miniaturization and sensorization, the key trend driving the global congestive heart failure treatment devices sector is integration of remote monitoring and data analytics, because continuous physiologic insights enable earlier clinical intervention and measurable reductions in readmissions. When hospitals and providers deploy implantable sensors or wearable telemetry, clinicians can adjust medications or schedule procedures proactively, and studies of CardioMEMS and telemonitoring demonstrate fewer emergency visits. That clinical benefit drives payer willingness to reimburse and encourages manufacturers to invest in AI platforms, which in turn expands partnerships and penetration into emerging markets where scalable models address capacity constraints.
How is Ai Improving Remote Monitoring in the Congestive Heart Failure Treatment Devices Market?
AI is improving the way we monitor patients with congestive heart failure through remote monitoring of implanted devices that treat this disease. Remote monitoring allows clinicians to use predictive algorithms to detect early signs of decompensation, use multiple types of data from device data and wearables, and automate triage processes to reduce the alert burden on clinicians. With remote monitoring, we are moving away from episodic clinic visits towards proactive, home care services supported by connected devices and diagnostic algorithms. As a result, there is an increasing demand for preventative cardiac care and more efficient workflows in this market.
In February 2026, Abbott unveiled its Assert IQ insertable cardiac monitor with cloud based AI that classifies episodes and cuts false positives, helping clinics prioritize patients and scale remote workflows. This innovation supports market efficiency by reducing clinician workload and enabling broader deployment of continuous heart failure monitoring.
Market snapshot - (2026-2033)
Global Market Size
USD 6.2 Billion
Largest Segment
Pacemakers
Fastest Growth
Remote Heart Failure Monitoring Devices
Growth Rate
5.69% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global congestive heart failure treatment devices market is segmented by product type, therapy type, modality, patient type, end user and region. Based on product type, the market is segmented into Ventricular Assist Devices (VADs), Implantable Cardioverter Defibrillators (ICDs), Cardiac Resynchronization Therapy (CRT) Devices, Pacemakers, Intra-Aortic Balloon Pumps (IABP), Extracorporeal Membrane Oxygenation (ECMO) Systems, Total Artificial Hearts (TAH), Remote Heart Failure Monitoring Devices and Other Heart Failure Support Devices. Based on therapy type, the market is segmented into Mechanical Circulatory Support, Rhythm Management Therapy, Cardiac Resynchronization Therapy, Hemodynamic Monitoring and Temporary Cardiac Support Therapy. Based on modality, the market is segmented into Implantable Devices and External Devices. Based on patient type, the market is segmented into Acute Heart Failure, Chronic Heart Failure and End-Stage Heart Failure. Based on end user, the market is segmented into Hospitals, Cardiac Care Centers, Ambulatory Surgical Centers and Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Based on the global congestive heart failure treatment devices market growth, ventricular assist devices segment dominates because these devices provide definitive hemodynamic support for patients with advanced heart failure, serving as bridge to recovery, transplant, or long term therapy. Their clinical maturity, demonstrated patient outcome improvements, and strong physician preference drive widespread adoption. Continued engineering refinements, miniaturization, and durable power and driveline solutions enhance reliability, which in turn sustains hospital investment, specialist training, and payer recognition.
However, remote heart failure monitoring devices are emerging as the most rapidly expanding area, driven by digital integration, patient demand for home based care, and predictive analytics that enable early intervention. Growing interoperability with electronic records and wearables, along with lower barriers to outpatient deployment, accelerates clinical adoption and creates new service and device revenue streams.
Mechanical circulatory support segment leads because it directly addresses severe circulatory insufficiency through a range of therapies from temporary pumps to long term assist devices, providing critical salvage and durable treatment options. Clinical guidelines for heart surgery emphasize Multidisciplinary Heart Teams to select high priority treatments for people who present with life threatening diseases. Strong clinical proof that patients benefit from both longer lives and better quality of life supports hospitals using these new designs and encourages manufacturers to produce them at a higher rate.
Meanwhile, hemodynamic monitoring is witnessing strongest growth momentum as implantable and ambulatory sensors deliver actionable data for earlier decompensation detection and proactive management. Advances in sensor technology, analytics platforms, and payer interest in preventing admissions drive adoption. This trend opens markets for integrated device software offerings and fosters partnerships between device makers, digital health firms, and care providers.
To get detailed segments analysis, Request a Free Sample Report
As per the global congestive heart failure treatment devices market share, North America commands the industry due to concentrated clinical expertise, established reimbursement frameworks, and a mature medical device ecosystem that supports innovation and commercial scale up. Collaboration between academic institutions, industry, and specialty physicians is critical for accelerating device acceptance and continual device improvement. A regulatory pathway is needed to allow for safety as well as prompt access to devices, and to facilitate investment and launch of devices into the marketplace. Reliable infrastructure (hospitals) and a high level of diagnostic/procedure capability enable devices to be extensively utilized in both implantable and non-implantable forms of therapy. Active clinician participation in both trial testing and guideline development will endorse acceptance of devices as clinical practices.
Congestive heart failure treatment devices market in United States is defined by leading clinical research centers, early adoption by cardiology units, and broad industry presence. High procedural volume across tertiary hospitals supports swift integration of implantable devices and advanced diagnostics. Coordinated care pathways and multidisciplinary teams enable device interventions and follow up. Established vendor partnerships with hospital systems and strong clinical training programs effectively improve market uptake and clinician confidence.
Congestive heart failure treatment devices market in Canada reflects a concentrated hospital network with coordinated procurement and emphasis on health technology assessment. As specialized cardiac centers lead the way in using implantable and monitoring solutions, regional centers will emphasize access and follow-up. Collaboration between public payers, clinicians and suppliers will define how devices will be evaluated and deployed after the evaluation. Training activities and supplier service models will allow ongoing use of devices and help clinicians become familiar with using them in care settings.
Based on global congestive heart failure treatment devices regional forecast, Europe is experiencing rapid expansion driven by harmonized regulatory standards that facilitate device market entry and cross-border collaboration. The presence of robust clinical networks and well-established cardiology facilities in key geographic areas will be a major factor in expediting the progression of advanced therapeutic & monitoring device adoption. Payers have increasingly accepted value-based device solutions, allowing for more structured reimbursement pathways. The emergence of innovation hubs along with an increasing number of specialty suppliers will also facilitate the diversification and localization of manufacturing for products. Additionally, the alignment of guidelines across multiple countries and collaboration with professional societies will facilitate the standardization of clinical practice, and EU-level initiatives will encourage the generation of clinical evidence.
Congestive heart failure treatment devices market in Germany benefits from a dense network of university medical centers, cardiology programs, and a supportive industrial base for medical technology. Strong hospital infrastructure enables complex device implantation and follow up. National clinical guidelines and procurement foster systematic adoption. The presence of manufacturers and collaboration with clinical trials speed up the approval of devices, while by providing focused training and reimbursement clarification will help provide a path for devices to be used and integrated into heart failure clinical pathways.
Congestive heart failure treatment devices market in United Kingdom is characterized by strong research-clinical collaboration, health system commissioning, and focused adoption initiatives. Pilot programs and specialist cardiac centers support evaluation and implementation of device therapies and remote monitoring. Working with vendors to provide training for clinicians and generate evidence to support adoption, along with government policies that ensure outcome-focused care can create sustained support for these models to continue growing.
Congestive heart failure treatment devices market in France is emerging via strengthened hospital capabilities, growing clinical interest, and investment in cardiac services. Regional centers create specialized knowledge in implanting devices and monitoring devices from a distance while national level health authorities focus on evaluation and utilisation. Collaboration between academic and industry partners helps with the piloting of projects, which support evidence generation. Improvements to clinician training as well as purchasing practices are facilitating continued integration of medical device therapy into care pathways for patients.
As per global congestive heart failure treatment devices regional outlook, Asia Pacific is strengthening its role through concentrated investment in clinical research, technological innovation, and localized manufacturing that support scalable deployment of congestive heart failure devices. Regulatory agencies are continuing to communicate with these industries about creating less complex pathways for implantable devices and balancing development with safety concerns. Collaboration between large manufacturers with global presence and smaller technology companies in the region has allowed for faster development and product adaptation to fit the specific needs of local clinical settings. Training/education of physicians, measurement of outcomes, and integration of device use with the overall healthcare system are critical elements to increasing long-term acceptance of implantable devices. Additionally, improvements in hospital capabilities and the creation of additional specialist networks throughout the rest of the world will help to ensure that there is significant growth in use of implantable devices in the global market.
Congestive heart failure treatment devices market in Japan is driven by established clinical research centers, widespread adoption in advanced hospitals, and a capable domestic medical technology sector. Collaboration between local manufacturers and international firms adapts devices to clinical and regulatory needs. Focus on postmarket evidence generation, clinician training, and integrated care pathways supports sustained adoption. Hospital readiness and specialist expertise enable complex device procedures and ongoing patient monitoring across settings.
Congestive heart failure treatment devices market in South Korea is supported by modern hospital systems, technological innovation, and close industry clinical collaboration. The focus on the integration of digital health and remote monitoring into implantable therapies has been made easier as a result of national clinical evaluation programs for clinicians and by providing appropriate training for them. The increased number of specialist networks, along with the provision of more efficient pathways to hospitals, offer improved implementation and ongoing management of patients across settings.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Advancements In Device Technology
Rising Prevalence Of Heart Failure
High Cost Of Advanced Devices
Regulatory Approval Complexity
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape for global congestive heart failure treatment devices market outlook is defined by incumbent strategic plays and rapid startup innovation. Large medtech firms pursue collaborations and licensing deals to secure monitoring and device pipelines, for example Medtronic’s strategic collaboration with Orchestra BioMed to develop AVIM therapy. Venture backed startups push device and data driven approaches, exemplified by Cardiosense’s Series A and Corveus Medical’s catheter neuromodulation prototype.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global congestive heart failure treatment devices industry is driven primarily by a rising prevalence of heart failure among aging populations and chronic disease burdens, with a second major driver being rapid integration of remote monitoring, sensorization and AI-enabled analytics that enable earlier intervention and reduced readmissions. Growth is tempered by the high cost of advanced devices which limits adoption and reimbursement in resource-constrained settings. North America remains the dominant region owing to mature clinical infrastructure, favorable reimbursement and strong commercialization networks, while the ventricular assist devices segment leads the market because of its definitive hemodynamic support and established clinical outcomes.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 6.2 Billion |
| Market size value in 2033 | USD 10.2 Billion |
| Growth Rate | 5.69% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Congestive Heart Failure Treatment Devices Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Congestive Heart Failure Treatment Devices Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Congestive Heart Failure Treatment Devices Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Congestive Heart Failure Treatment Devices Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Congestive Heart Failure Treatment Devices Market size was valued at USD 6.2 Billion in 2024 and is poised to grow from USD 6.55 Billion in 2025 to USD 10.2 Billion by 2033, growing at a CAGR of 5.69% during the forecast period (2026-2033).
The competitive landscape for global congestive heart failure treatment devices is defined by incumbent strategic plays and rapid startup innovation. Large medtech firms pursue collaborations and licensing deals to secure monitoring and device pipelines, for example Medtronic’s strategic collaboration with Orchestra BioMed to develop AVIM therapy. Venture backed startups push device and data driven approaches, exemplified by Cardiosense’s Series A and Corveus Medical’s catheter neuromodulation prototype. 'Medtronic plc', 'Abbott Laboratories', 'Boston Scientific Corporation', 'BIOTRONIK SE & Co. KG', 'Abiomed', 'LivaNova PLC', 'Terumo Corporation', 'MicroPort Scientific Corporation', 'Getinge AB', 'Edwards Lifesciences Corporation', 'Teleflex Incorporated', 'B. Braun SE', 'Jarvik Heart, Inc.', 'Berlin Heart GmbH', 'Syncardia Systems, LLC', 'OSYPKA Medical GmbH', 'Oscor Inc.', 'Shree Pacetronix Ltd.', 'Calon Cardio-Technology Ltd.', 'EBR Systems, Inc.'
Rapid improvements in device design, materials, sensor integration, and battery longevity have enhanced the safety, efficacy, and patient comfort of congestive heart failure treatment devices. These technological enhancements enable more reliable monitoring, targeted therapy delivery, and simplified implantation or outpatient management, which increases clinician confidence and expands indications for use. As a result, adoption by healthcare providers and acceptance among patients rise, facilitating broader market uptake and stimulating investment and further innovation in device development across multiple care settings and geographies.
Remote Hemodynamic Monitoring: Adoption of implantable and wearable sensors enabling continuous physiologic tracking is reshaping chronic heart failure management. Clinicians leverage remote hemodynamic insights to tailor therapy, personalize medication titration, and proactively identify clinical deterioration before symptomatic decline. Integration with telehealth platforms fosters closer patient engagement, reduces reliance on episodic visits, and supports longitudinal care pathways. Payers and providers increasingly view remote monitoring as an enabler for care coordination, while device developers focus on interoperability, comfort, and actionable decision support that improves outcomes.
Why does North America Dominate the Global Congestive Heart Failure Treatment Devices Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
